11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Solona

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Flukonazol

Flukonazol

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Nørgaard M, Pedersen L, Gislum M, Erichsen R, Søgaard KK, Schønheyder HC, Sørensen HT. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother 2008;62:172-6.

  2. Mastroiacovo P, Mazzone T, Botto LD et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996;175:1645-50.

  3. Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol. 1994;46:115-8.

  4. Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy. 1999;19:221-2.

  5. Sorensen HT, Nielsen GL, Olesen C, Larsen H, Steffensen FH, Schønheyder HC et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol. 1999;48:234-8.

  6. Mølgaard-Nielsen D, Pasternak B, Hviid A. Oral fluconazole during pregnancy and risk of birth defects. N Engl J Med. 2013;369:2061-2.

  7. Howley MM, Carter TC, Browne ML, Romitti PA, Cunniff CM, Druschel CM et al. Fluconazole use and birth defects in the National Birth Defects Prevention Study. Am J Obstet Gynecol. 2016;214:657e1-9.

  8. Yanmin Z, Bateman TB, Gray KJ, Hernandez-Diaz S, Mogun H, Straub L, Huybrechts KF. Oral Fluconazole Use in the First Trimester and Risk of Congenital Malformations: Population Based Cohort Study. BMJ. 2020 May;20(369):0.

  9. Bérard A, Sheehy O, Zhao JP, Gorgui J, Bernatsky S, de Moura CS et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ. 2019;191(7):E179-E187.

  10. Mølgaard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. JAMA. 2016;315:58-67.

  11. Lopez-Rangel E, VanAllen MI. Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol. 2005;73:919-23.

  12. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997;72:253-6.

  13. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22:336-40.

  14. Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J. 1992;11:1062-4.

  15. Kragie L, Turner SD, Patten CJ, Crespi CL, Stresser DM. Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay. Endocr Res. 2002;28:129-40.

  16. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69:751-5.

  1. Nørgaard M, Pedersen L, Gislum M, Erichsen R, Søgaard KK, Schønheyder HC, Sørensen HT. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother 2008;62:172-6.
  2. Mastroiacovo P, Mazzone T, Botto LD et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996;175:1645-50.
  3. Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol. 1994;46:115-8.
  4. Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy. 1999;19:221-2.
  5. Sorensen HT, Nielsen GL, Olesen C, Larsen H, Steffensen FH, Schønheyder HC et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol. 1999;48:234-8.
  6. Mølgaard-Nielsen D, Pasternak B, Hviid A. Oral fluconazole during pregnancy and risk of birth defects. N Engl J Med. 2013;369:2061-2.
  7. Howley MM, Carter TC, Browne ML, Romitti PA, Cunniff CM, Druschel CM et al. Fluconazole use and birth defects in the National Birth Defects Prevention Study. Am J Obstet Gynecol. 2016;214:657e1-9.
  8. Yanmin Z, Bateman TB, Gray KJ, Hernandez-Diaz S, Mogun H, Straub L, Huybrechts KF. Oral Fluconazole Use in the First Trimester and Risk of Congenital Malformations: Population Based Cohort Study. BMJ. 2020 May;20(369):0.
  9. Bérard A, Sheehy O, Zhao JP, Gorgui J, Bernatsky S, de Moura CS et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ. 2019;191(7):E179-E187.
  10. Mølgaard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. JAMA. 2016;315:58-67.
  11. Lopez-Rangel E, VanAllen MI. Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol. 2005;73:919-23.
  12. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997;72:253-6.
  13. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22:336-40.
  14. Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J. 1992;11:1062-4.
  15. Kragie L, Turner SD, Patten CJ, Crespi CL, Stresser DM. Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay. Endocr Res. 2002;28:129-40.
  16. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69:751-5.